Clinical trialsCompany release

GH Research moves GH001 to single-dose inhaler regimen as FDA feedback on depression plan is positive

GH Research PLC (GHRS) · Fri 13 Nov 2026

The company says final Phase 1 device data support one fixed dose per visit, with an End-of-Phase 2 meeting for treatment-resistant depression expected in Q1 2027.

GH Research PLC has said final Phase 1 results for its new GH001 aerosol delivery device support reducing dosing from three doses to a single fixed dose per visit. The data come from the HV-106 study in healthy volunteers, in which 7 of 8 participants reached a peak experience, according to the company's November 2026 corporate update.

The company also reported positive initial feedback from the US Food and Drug Administration on development of mebufotenin in treatment-resistant depression (TRD). An End-of-Phase 2 meeting is expected in the first quarter of 2027, with a pivotal programme to start soon afterwards.

GH Research is also targeting the start of a pivotal programme in postpartum depression in the second half of 2027. The update did not, in the information available, detail trial designs or endpoints for either indication.

On the corporate side, the company named Vanina Popova as Chief Development Officer. It reported cash of $350.6m at 30 September 2026.

What it means for your team

  • A move to a single fixed dose per visit would simplify the regimen that regulators will review, but the FDA's view will only become clear after the Q1 2027 End-of-Phase 2 meeting.
  • Device and dosing changes in inhaled products typically require supporting data; teams tracking the programme should watch how the new aerosol device is carried into pivotal studies.
  • Two potential pivotal programmes, in TRD and postpartum depression, signal a widening late-stage pipeline for mebufotenin over 2027.

Company's press release (SEC filing): GH Research PLC ↗

Article written by VigiEye from the official source (GH Research PLC). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →